🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

514 results for “Vir” Clear

  1. HCQ01

    Sana Biotechnology

    2019 Novel Coronavirus

    phase 2 small molecule active

    2 trials

  2. HEPCLUDEX 2 mg powder for solution for injection, VIR-2218, VIR-3434

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 2 small molecule active

    1 trial

  3. HH-003(20mg/kg)

    Huahui Health

    Chronic Hepatitis Delta Virus Infection

    phase 2 mab completed

    1 trial

  4. Hexyon suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)., MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, RotaTeq oral solution Rotavirus vaccine (live), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), MenPenta SD, Prevenar 13 suspension for in

    Sanofi-aventis Healthcare Pty Ltd

    Meningococcal immunization

    phase 2 small molecule active

    1 trial

  5. INO-4700

    INOVIO PHARMACEUTICALS, INC.

    Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

    phase 2 small molecule completed

    1 trial

  6. ISIS 14803, peginterferon alfa, ribavirin

    IONIS PHARMACEUTICALS INC

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  7. Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 2 small molecule completed

    1 trial

  8. Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution

    Takeda

    Immune Thrombocytopenic Purpura (ITP)

    phase 2 small molecule completed

    1 trial

  9. Inactivated types 1, 2, and 3 poliovirus, D antigens

    Sanofi Pasteur

    Poliomyelitis

    phase 2 mab completed

    1 trial

  10. Ixazomib 1 MG

    Takeda

    Human Immunodeficiency Virus (HIV)

    phase 2 small molecule completed

    1 trial

  11. Live attenuated Japanese encephalitis virus; Yellow fever virus

    Sanofi Pasteur

    Japanese Encephalitis

    phase 2 mab completed

    1 trial

  12. Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)

    Sinovac Research and Development Co.,

    Hand, Foot, and Mouth Disease (HFMD)

    phase 2 mab completed

    1 trial

  13. Lumicitabine

    Janssen Cilag International NV

    Respiratory Syncytial Viruses

    phase 2 small molecule terminated

    1 trial

  14. Lumicitabine

    Janssen Cilag International NV

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    1 trial

  15. M5049

    Serono Europe Limited

    Coronavirus Disease 2019

    phase 2 small molecule completed

    1 trial

  16. MAU868

    Vera Therapeutics

    BK Virus Infection

    phase 2 small molecule completed

    1 trial

  17. MEDI8897

    MedImmune

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    1 trial

  18. MP-424 (Telaprevir)

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  19. Maraviroc

    Pfizer

    Arthritis, Rheumatoid

    phase 2 small molecule terminated

    1 trial

  20. Maribavir

    Takeda

    Cytomegalovirus Infection

    phase 2 small molecule completed

    1 trial

  21. Motavizumab, palivizumab

    MedImmune

    Respiratory Syncytial Virus Infections

    phase 2 mab completed

    1 trial

  22. Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Prevenar 13 suspension for injection pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Rotarix oral suspension in pre-filled oral applicator Rotavirus vaccine, live, Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IP

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 small molecule active

    1 trial

  23. NoV GI.1/GII.4 Bivalent VLP Vaccine

    Takeda

    Norovirus

    phase 2 mab completed

    1 trial

  24. Norovirus Bivalent VLP Vaccine

    Takeda

    Norovirus Prevention

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources